Tissue Group SLC2A2 SLC2A4 HK1 NOS2 PRKCA
Liver High dose 6.25 ± 5.06 3.00 ± 1.41 0.38 ± 0.25 5.25 ± 4.11 2.13 ± 2.72
Intermediate dose 7.75 ± 4.92 4.00 ± 4.24 2.00 ± 1.78 5.25 ± 5.74 3.75 ± 3.86
Low dose 7.75 ± 5.31 1.75 ± 1.50 3.12 ± 3.71 2.00 ± 2.83 5.25 ± 5.74
Negative cont. 1.50 ± 1.00 5.75 ± 2.87 0.25 ± 0.29 6.00 ± 5.48 5.50 ± 4.80
Kidney High dose 8.50 ± 1.91 3.87 ± 1.25 5.62 ± 2.84 7.00 ± 3.32 3.87 ± 1.93a
Intermediate dose 4.75 ± 4.25 3.12 ± 3.20 3.87 ± 3.22 4.12 ± 4.77 5.87 ± 3.40
Low dose 3.37 ± 2.95b 4.75 ± 2.96 1.00 ± 1.35a 4.37 ± 4.53 3.50 ± 1.47a
Negative cont. 4.12 ± 2.39 4.25 ± 3.40 7.00 ± 1.35 5.00 ± 5.08 8.37 ± 3.09
ap < 0.05 compared to the negative control group.
bp < 0.05 compared to the high-dose group.
Table 2: The effect of GlcNs on immunohistochemistry scores (see Methods) in liver and kidney tissue samples (mean ± standard deviation, n = 4).